News

Receptor Tyrosine Protein Kinase ERBB 3 Pipeline Report: Evaluates Market on Mechanism of Action (MoA), Drug Target, Route of Administration (RoA) and Molecule Type

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) – Receptor tyrosine-protein kinase erbB-3 or HER3 is a membrane bound protein encoded by the ERBB3 gene. It belongs to tyrosine-protein kinase family. It plays an essential role as cell surface receptor for neuregulins. It binds to neuregulin-1 (NRG1) and is activated by it. It also activated by CSPG5.

Report Source: https://www.themarketreports.com/report/receptor-tyrosine-protein-kinase-erbb-3-proto-oncogene-like-protein-c-erbb-3-or-tyrosine-kinase-type-cell-surface-receptor-her3-or-her3-or-erbb3-or-ec-27101-pipeline-review-h1

Scope

  • The report reviews Receptor Tyrosine Protein Kinase ERBB 3 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 targeted therapeutics and enlists all their major and minor projects
  • The report assesses Receptor Tyrosine Protein Kinase ERBB 3 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 3 targeted therapeutics

Purchase this report at: https://www.themarketreports.com/report/buy-now/1488125

Reasons To Buy

  • Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 3
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 3 development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

  • Aslan Pharmaceuticals Ltd
  • AstraZeneca Plc
  • AVEO Pharmaceuticals Inc
  • Celldex Therapeutics Inc
  • Etubics Corp
  • Hanmi Pharmaceuticals Co Ltd
  • Hummingbird Bioscience Pte Ltd
  • Imugene Ltd
  • MediaPharma SRL
  • Merus NV
  • Novartis AG
  • SunRock Biopharma SL
  • Symphogen A/S
  • Taiho Pharmaceutical Co Ltd
  • Takis Srl
  • XuanZhu Pharma Co Ltd

Got a question; ask us at: https://www.themarketreports.com/report/ask-your-query/1488125